GlassScriptPhysician profile
Lorelei Natasha Bourla
NPI 1144649260
$571.45
in general payments reported to CMS, 2019-2025
12 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $145 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545 · Consulting Fee: $26.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.71 |
| Consulting Fee | $26.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $139.56 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $90.47 | 2024-2025 | |
| Glaxosmithkline, LLC. | $81.27 | 2024-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $79.88 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Ars Pharmaceuticals Operations, INC. | $29.11 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $26.74 | 2025 | |
| Biocryst US Sales Co., LLC | $26.55 | 2024 | Orladeyo |
| Amgen INC. | $26.01 | 2025 | Tezspire |
| Csl Behring | $24.93 | 2025 | Hizentra |
| Viatris Specialty LLC | $16.77 | 2025 | Yupelri |
| Pharming Healthcare, INC. | $16.10 | 2025 | Ruconest |
| Genzyme Corporation | $14.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorelei Bourla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.